Searched for: subject%3A%22Thrombin%255C%2Bactivatable%255C%2Bfibrinolysis%255C%2Binhibitor%22
(1 - 6 of 6)
document
Rijken, D.C. (author), Hoegee-de Nobel, E. (author), Jie, A.F.H. (author), Atsma, D.E. (author), Schalij, M.J. (author), Nieuwenhuizen, W. (author), TNO Kwaliteit van Leven (author)
Background: The development of global tests for the fibrinolytic capacity in blood is hampered by the low base-line fibrinolytic activity in blood, by the involvement of both plasmatic components and blood cells in the fibrinolytic system and by the loss of fibrinolytic activity as a result of the action of plasminogen activator inhibitor-1 (PAI...
article 2008
document
Bertina, R.M. (author), van Tilburg, N.H. (author), Haverkate, F. (author), Bouma, B.N. (author), von dem Borne, P.A.K. (author), Meijers, J.C.M. (author), Campbell, W. (author), Eaton, D. (author), Hendriks, D.F. (author), Willemse, J.L. (author), TNO Kwaliteit van Leven (author)
CAS: blood clotting factor 11, 9013-55-2; thrombin, 9002-04-4; tissue plasminogen activator, 105913-11-9; protein C, 60202-16-6; Carboxypeptidase U, 3.4.17.20; Protein C; Tissue Plasminogen Activator, 3.4.21.68
article 2006
document
GuimarĂ£es, A.H.C. (author), van Tilburg, N.H. (author), Vos, H.L. (author), Bertina, R.M. (author), Rijken, D.C. (author)
Thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels exhibit a large interindividual variability in which genetic control seems to play a major role. However, recent reports have questioned the association between TAFI concentration and genotype, suggesting that variable antibody reactivity towards TAFI isoforms, particularly the...
article 2004
document
de Maat, M.P.M. (author), Jansen, M.W.J.C. (author), Hille, E.T.M. (author), Vos, H. (author), Bloemenkamp, K.W.M. (author), Buitendijk, S.E. (author), Helmerhorst, F.M. (author), Wladimiroff, J.W. (author), Bertina, R.M. (author), de Groot, C.J.M. (author), TNO Preventie en Gezondheid (author)
Recently, it has been proposed that abnormalities in coagulation and fibrinolysis contribute to the development of preeclampsia by increasing the thrombotic tendency. This hypothesis was tested in women who have had preeclampsia (cases) compared with matched controls. Polymorphisms in the thrombophilia genes {plasminogen activator inhibitor type...
article 2004
document
Gaubius Instituut TNO (author), Walker, J.B. (author), Hughes, B. (author), James, I. (author), Haddock, P. (author), Kluft, C. (author), Bajzar, L. (author)
Two competitive inhibitors of TAFIa (activated thrombin-activable fibrinolysis inhibitor), 2-guanidinoethyl-mercaptosuccinic acid and potato tuber carboxypeptidase inhibitor, variably affect fibrinolysis of clotted human plasma. Depending on their concentration, the inhibitors shortened, prolonged, or had no effect on lysis in vitro. The...
article 2003
document
TNO Preventie en Gezondheid (author), Meijers, J.C.M. (author), Oudijk, E.J.D. (author), Mosnier, L.O. (author), Bos, R. (author), Bouma, B.N. (author), Nieuwenhuis, H.K. (author), Fijnheer, R. (author)
Acute promyelocytic leukaemia (APL) is a disease that is distinguished from other leukaemias by the high potential for early haemorrhagic death. Several processes are involved, such as disseminated intravascular coagulation and hyperfibrinolysis. Recently, TAFI (thrombin-activatable fibrinolysis inhibitor) was identified as a link between...
article 2000
Searched for: subject%3A%22Thrombin%255C%2Bactivatable%255C%2Bfibrinolysis%255C%2Binhibitor%22
(1 - 6 of 6)